GUTS - NASDAQ
Fractyl Health, Inc. Common Stock
$0.76
-3.1%Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
At a Glance
Live SnapshotFractyl Health, Inc. Common Stock Management Team
Ms. Lisa A. Davidson MBA
Chief Financial Officer & Treasurer
Compensation
$580,985
Dr. Timothy J. Kieffer Ph.D.
Chief Scientific Officer
Compensation
$140,638
Dr. Harith Rajagopalan M.D., Ph.D.
Co-Founder, Chief Executive Officer & Director
Compensation
$879,562
Mr. Jay D. Caplan BSEE, MBA
Co-Founder, Chief Product Officer & President
Compensation
$611,177
Ms. Sarah S. Toomey Esq.
General Counsel & Corporate Secretary
Compensation
$479,363
Mr. Jon Fitzgerald
Senior Vice President of Regulatory, Quality & Clinical
Ms. Jessica Cotrone
Vice President of Corporate Communications
Fractyl Health, Inc. Common Stock Insider Positioning
During the last 12 months, insiders have purchased $378K and sold $56K worth of GUTS shares, resulting in $322K of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
10.4K
20.00K
0
0.00
+20K
+$20K
9-12 Months
157.5K
357.52K
21.0K
55.99K
+302K
+$302K
Top Buyers
Schulman Amy W
Director
$51K
Meanwell Clive
Director
$51K
Bradley William
Director
$51K
Barnes Kelly Ann
Director
$51K
Royan Ajay
Director, 10 Percent Owner:
$51K
Top Sellers
Thompson Christopher Charles
Director
$56K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $322K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
GUTS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | April 23, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | August 25, 2025 | October 03, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | April 24, 2025 | June 11, 2025 | 2025 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.